205 related articles for article (PubMed ID: 38235131)
1. NLRC5 overexpression in ovarian tumors remodels the tumor microenvironment and increases T-cell reactivity toward autologous tumor-associated antigens.
Rodriguez GM; Yakubovich E; Murshed H; Maranda V; Galpin KJC; Cudmore A; Hanna AMR; Macdonald E; Ramesh S; Garson K; Vanderhyden BC
Front Immunol; 2023; 14():1295208. PubMed ID: 38235131
[TBL] [Abstract][Full Text] [Related]
2. NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
Yoshihama S; Roszik J; Downs I; Meissner TB; Vijayan S; Chapuy B; Sidiq T; Shipp MA; Lizee GA; Kobayashi KS
Proc Natl Acad Sci U S A; 2016 May; 113(21):5999-6004. PubMed ID: 27162338
[TBL] [Abstract][Full Text] [Related]
3. BMI1 induces ubiquitination and protein degradation of Nod-like receptor family CARD domain containing 5 and suppresses human leukocyte antigen class I expression to induce immune escape in non-small cell lung cancer.
Lu ZH; Tu GJ; Fu SL; Shang K; Peng SJ; Chen L; Gu XJ
Kaohsiung J Med Sci; 2022 Dec; 38(12):1190-1202. PubMed ID: 36194200
[TBL] [Abstract][Full Text] [Related]
4. NLRC5 deficiency has a moderate impact on immunodominant CD8
Sun T; Ferrero RL; Girardin SE; Gommerman JL; Philpott DJ
Immunol Cell Biol; 2019 Jul; 97(6):552-562. PubMed ID: 30768806
[TBL] [Abstract][Full Text] [Related]
5. Deficiency of the NOD-Like Receptor NLRC5 Results in Decreased CD8
Lupfer CR; Stokes KL; Kuriakose T; Kanneganti TD
J Virol; 2017 Sep; 91(17):. PubMed ID: 28615208
[TBL] [Abstract][Full Text] [Related]
6. LC3 and NLRC5 interaction inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer.
Zhan L; Zhang J; Zhang J; Liu X; Zhu S; Shi Y; He Y; Wang W; Fan Y; Tang Z; Chen G; Wei B; Cao Y
Cancer Lett; 2022 Mar; 529():37-52. PubMed ID: 34974132
[TBL] [Abstract][Full Text] [Related]
7. Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance.
Vijayan S; Sidiq T; Yousuf S; van den Elsen PJ; Kobayashi KS
Immunogenetics; 2019 Mar; 71(3):273-282. PubMed ID: 30706093
[TBL] [Abstract][Full Text] [Related]
8. HSP27 modulates tumoural immune evasion by enhancing STAT3-mediated upregulation of PD-L1 and NLRC5 in ovarian cancer.
Fezza M; Hilal G; Tahtouh R; Moubarak M; Atallah D
Ecancermedicalscience; 2023; 17():1526. PubMed ID: 37113720
[TBL] [Abstract][Full Text] [Related]
9. NLRC5 regulates MHC class I antigen presentation in host defense against intracellular pathogens.
Yao Y; Wang Y; Chen F; Huang Y; Zhu S; Leng Q; Wang H; Shi Y; Qian Y
Cell Res; 2012 May; 22(5):836-47. PubMed ID: 22491475
[TBL] [Abstract][Full Text] [Related]
10. Coronavirus Porcine Deltacoronavirus Upregulates MHC Class I Expression through RIG-I/IRF1-Mediated NLRC5 Induction.
Liu X; Yin L; Xue M; Chen J; Li L; Fu F; Feng L; Liu P
J Virol; 2022 Apr; 96(7):e0015822. PubMed ID: 35311551
[TBL] [Abstract][Full Text] [Related]
11. NLRC5 regulates expression of MHC-I and provides a target for anti-tumor immunity in transmissible cancers.
Ong CEB; Patchett AL; Darby JM; Chen J; Liu GS; Lyons AB; Woods GM; Flies AS
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1973-1991. PubMed ID: 33797607
[TBL] [Abstract][Full Text] [Related]
12. Respiratory Syncytial Virus Infection Upregulates NLRC5 and Major Histocompatibility Complex Class I Expression through RIG-I Induction in Airway Epithelial Cells.
Guo X; Liu T; Shi H; Wang J; Ji P; Wang H; Hou Y; Tan RX; Li E
J Virol; 2015 Aug; 89(15):7636-45. PubMed ID: 25972545
[TBL] [Abstract][Full Text] [Related]
13. Expression regulation and function of NLRC5.
Yao Y; Qian Y
Protein Cell; 2013 Mar; 4(3):168-75. PubMed ID: 23483478
[TBL] [Abstract][Full Text] [Related]
14. Emerging Major Histocompatibility Complex Class I-Related Functions of NLRC5.
Chelbi ST; Dang AT; Guarda G
Adv Immunol; 2017; 133():89-119. PubMed ID: 28215281
[TBL] [Abstract][Full Text] [Related]
15. NLRC5 deficiency selectively impairs MHC class I- dependent lymphocyte killing by cytotoxic T cells.
Staehli F; Ludigs K; Heinz LX; Seguín-Estévez Q; Ferrero I; Braun M; Schroder K; Rebsamen M; Tardivel A; Mattmann C; MacDonald HR; Romero P; Reith W; Guarda G; Tschopp J
J Immunol; 2012 Apr; 188(8):3820-8. PubMed ID: 22412192
[TBL] [Abstract][Full Text] [Related]
16. Selective autophagy of NLRC5 promotes immune evasion of endometrial cancer.
Zhan L; Zhang J; Wei B; Cao Y
Autophagy; 2022 Apr; 18(4):942-943. PubMed ID: 35174769
[TBL] [Abstract][Full Text] [Related]
17. MHC class I transactivator NLRC5 in host immunity, cancer and beyond.
Cho SX; Vijayan S; Yoo JS; Watanabe T; Ouda R; An N; Kobayashi KS
Immunology; 2021 Mar; 162(3):252-261. PubMed ID: 32633419
[TBL] [Abstract][Full Text] [Related]
18. NLRC5 elicits antitumor immunity by enhancing processing and presentation of tumor antigens to CD8(+) T lymphocytes.
Rodriguez GM; Bobbala D; Serrano D; Mayhue M; Champagne A; Saucier C; Steimle V; Kufer TA; Menendez A; Ramanathan S; Ilangumaran S
Oncoimmunology; 2016 Jun; 5(6):e1151593. PubMed ID: 27471621
[TBL] [Abstract][Full Text] [Related]
19. Targeting the immune microenvironment for ovarian cancer therapy.
Blanc-Durand F; Clemence Wei Xian L; Tan DSP
Front Immunol; 2023; 14():1328651. PubMed ID: 38164130
[TBL] [Abstract][Full Text] [Related]
20. The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy.
Shukla A; Cloutier M; Appiya Santharam M; Ramanathan S; Ilangumaran S
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
